FY2025 EPS Estimates for Aethlon Medical Boosted by Analyst

Aethlon Medical, Inc. (NASDAQ:AEMD) – Investment analysts at HC Wainwright boosted their FY2025 earnings estimates for shares of Aethlon Medical in a research note issued to investors on Wednesday, February 19th. HC Wainwright analyst V. Bernardino now anticipates that the medical equipment provider will post earnings per share of ($0.73) for the year, up from their previous forecast of ($0.92). HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Aethlon Medical’s current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Aethlon Medical’s Q4 2025 earnings at ($0.13) EPS and FY2026 earnings at ($0.49) EPS.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.09.

Separately, StockNews.com raised shares of Aethlon Medical to a “sell” rating in a research report on Wednesday.

Aethlon Medical Stock Down 4.3 %

Shares of Aethlon Medical stock opened at $0.58 on Friday. The firm has a market capitalization of $8.44 million, a P/E ratio of -0.37 and a beta of 1.88. The company has a 50 day moving average price of $0.66 and a 200 day moving average price of $0.49. Aethlon Medical has a 52 week low of $0.24 and a 52 week high of $1.85.

Hedge Funds Weigh In On Aethlon Medical

Hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC acquired a new position in Aethlon Medical in the 4th quarter worth approximately $25,000. Allegiance Financial Group Advisory Services LLC acquired a new position in Aethlon Medical in the 4th quarter worth approximately $26,000. Sassicaia Capital Advisers LLC acquired a new position in Aethlon Medical in the 4th quarter worth approximately $31,000. Virtu Financial LLC acquired a new position in Aethlon Medical in the 4th quarter worth approximately $81,000. Finally, Boothbay Fund Management LLC acquired a new position in Aethlon Medical in the 4th quarter worth approximately $186,000. Institutional investors and hedge funds own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.